Increasing Membrane Cholesterol Level Increases the Amyloidogenic Peptide by Enhancing the Expression of Phospholipase C

Journal of Neurodegenerative Diseases
Yoon Sun ChunSungkwon Chung

Abstract

Cerebral elevation of 42-residue amyloid β-peptide (Aβ42) triggers neuronal dysfunction in Alzheimer's disease (AD). Even though a number of cholesterol modulating agents have been shown to affect Aβ generation, the role of cholesterol in the pathogenesis of AD is not clear yet. Recently, we have shown that increased membrane cholesterol levels downregulates phosphatidylinositol 4,5-bisphosphate (PIP2) via activation of phospholipase C (PLC). In this study, we tested whether membrane cholesterol levels may affect the Aβ42 production via changing PIP2 levels. Increasing membrane cholesterol levels decreased PIP2 and increased secreted Aβ42. Supplying PIP2, by using a PIP2-carrier system, blocked the effect of cholesterol on Aβ42. We also found that cholesterol increased the expressions of β1 and β3 PLC isoforms (PLCβ1, PLCβ3). Silencing the expression of PLCβ1 prevented the effects of cholesterol on PIP2 levels as well as on Aβ42 production, suggesting that increased membrane cholesterol levels increased secreted Aβ42 by downregulating PIP2 via enhancing the expression of PLCβ1. Thus, cholesterol metabolism may be linked to Aβ42 levels via PLCβ1 expression and subsequent changes in PIP2 metabolism.

References

Apr 10, 1992·Science·J A Hardy, G A Higgins
Sep 27, 2000·Proceedings of the National Academy of Sciences of the United States of America·S OzakiG D Prestwich
May 4, 2002·Annual Review of Biophysics and Biomolecular Structure·Stuart McLaughlinDiana Murray
Dec 24, 2002·Biophysical Journal·Victor G RomanenkoIrena Levitan
Jan 8, 2003·The Journal of Cell Biology·Robert EhehaltKai Simons
Feb 19, 2004·Proceedings of the National Academy of Sciences of the United States of America·Roy G CutlerMark P Mattson
Sep 16, 2004·Nature Reviews. Molecular Cell Biology·Paul A Janmey, Uno Lindberg
Dec 8, 2004·The Journal of Cell Biology·Jose Abad-RodriguezCarlos G Dotti
Jan 13, 2006·Journal of Neurochemistry·Mostafa BentahirBart De Strooper
Jul 11, 2006·Journal of Neuroscience Research·Chinatsu HattoriShoichi Ishiura
Oct 13, 2006·Nature·Gilbert Di Paolo, Pietro De Camilli
Dec 13, 2006·Proceedings of the National Academy of Sciences of the United States of America·Natalie LandmanTae-Wan Kim
Feb 9, 2007·Journal of Neurochemistry·Dominic M Walsh, Dennis J Selkoe
May 16, 2008·The Journal of Biological Chemistry·Satoko OsawaYasuo Ihara
Jun 10, 2008·The Journal of Biological Chemistry·Pamela OsenkowskiDennis J Selkoe
Dec 18, 2009·Journal of Neurochemistry·Yoon Sun ChunSungkwon Chung
Mar 23, 2010·Biochimica Et Biophysica Acta·Kulandaivelu S Vetrivel, Gopal Thinakaran
Jun 29, 2010·Biochimica Et Biophysica Acta·Jack-Christophe CossecMarie-Claude Potier
Jan 25, 2011·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Catherine MarquerMarie-Claude Potier
Sep 8, 2011·The Journal of Biological Chemistry·Amelie EbkeHarald Steiner

❮ Previous
Next ❯

Citations

Mar 3, 2019·International Journal of Molecular Sciences·Igor I Krivoi, Alexey M Petrov

❮ Previous
Next ❯

Methods Mentioned

BETA
antisense oligonucleotides
Assay
ELISA
antisense oligonucleotide

Software Mentioned

Multi Gauge
ImageJ

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.